PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor
Citations Over TimeTop 10% of 2019 papers
Abstract
PF-06651600 was developed as an irreversible inhibitor of JAK3 with selectivity over the other three JAK isoforms. A high level of selectivity toward JAK3 is achieved by the covalent interaction of PF-06651600 with a unique cysteine residue (Cys-909) in the catalytic domain of JAK3, which is replaced by a serine residue in the other JAK isoforms. Importantly, 10 other kinases in the kinome have a cysteine at the equivalent position of Cys-909 in JAK3. Five of those kinases belong to the TEC kinase family including BTK, BMX, ITK, RLK, and TEC and are also inhibited by PF-06651600. Preclinical data demonstrate that inhibition of the cytolytic function of CD8+ T cells and NK cells by PF-06651600 is driven by the inhibition of TEC kinases. On the basis of the underlying pathophysiology of inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, alopecia areata, and vitiligo, the dual activity of PF-06651600 toward JAK3 and the TEC kinase family may provide a beneficial inhibitory profile for therapeutic intervention.
Related Papers
- → Selective inhibitors of the Janus kinase Jak3—Are they effective?(2014)58 cited
- → Janus kinase 3: the controller and the controlled(2011)23 cited
- → JAK3 Specific Kinase Inhibitors: When Specificity Is Not Enough(2011)18 cited
- → Structural Analysis of Janus Kinases.(2004)
- → Janus kinase-3 (JAK3; JAK-3)(2009)